Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
8
4
5
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
13%
1 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (8)
Trial Evaluating Hypo-fractionated Accelerated Versus Conventional Fractionated Adjuvant RT in Head & Neck Malignancies
Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform
Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors
Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN
Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)
Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma
Immune Response in Cervical Lymph Nodes of Patients With Head and Neck Cancer
Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations